EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals (NASDAQ: EYPT) shares fell roughly 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU missed its primary endpoint in wet age-related macular degeneration. If you owned EYPT shares when that result hit, you may have legal rights. Shareholders who lost money on EYPT are encouraged to submit their loss information now.
You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The prespecified primary endpoint was non-inferiority to on-label aflibercept in mean change in best-corrected visual acuity (BCVA) at Weeks 52 and 56. LUCIA failed to meet this endpoint: DURAVYU patients gained approximately 2.5 letters, compared with 6.1 letters for aflibercept patients, a between-group difference of −3.7 letters. The Company highlighted favorable secondary results, including a 38% reduction in treatment burden, with 52% of DURAVYU-treated eyes remaining supplement-free through Week 56. Despite these secondary benefits, the prespecified primary endpoint was not met.
EyePoint has since concluded its wet AMD pivotal trials early. Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of affected EYPT investors.
If your EYPT position took a hit, find out whether you can recover your losses or call (212) 363-7500.
Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the EYPT Investigation
Q: How much did EYPT stock drop? A: Shares fell approximately 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU missed its primary endpoint of non-inferiority to on-label aflibercept in wet AMD. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether EyePoint Pharmaceuticals made materially false or misleading statements regarding its DURAVYU wet AMD program. When the Company disclosed that the Phase 3 LUCIA trial missed its primary endpoint, the stock price declined sharply.
Q: What do EYPT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my EYPT shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.
Q: What if my EYPT losses are small — is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys’ fees and expenses are subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
